Dyne Therapeutics (DYN) Revenue & Revenue Breakdown
Dyne Therapeutics Revenue Highlights
00
Dyne Therapeutics Revenue by Period
Dyne Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | -100.00% |
| 2017-12-31 | $506.00M | -62.96% |
| 2016-12-31 | $1.37B | 62.23% |
| 2015-12-31 | $842.00M | -42.56% |
| 2014-12-31 | $1.47B | 48766.67% |
| 2013-12-31 | $3.00M | - |
| 2012-12-31 | $3.00M | -99.81% |
| 2011-12-31 | $1.58B | -31.77% |
| 2010-12-31 | $2.32B | -5.88% |
| 2009-12-31 | $2.47B | -30.46% |
| 2008-12-31 | $3.55B | 14.37% |
| 2007-12-31 | $3.10B | - |
Dyne Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Dyne Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $3.79M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2017-12-31 | $470.00M | 158.24% |
| 2017-09-30 | $182.00M | 0.55% |
| 2017-06-30 | $181.00M | 3.43% |
| 2017-03-31 | $175.00M | -77.88% |
| 2016-12-31 | $791.00M | 228.22% |
| 2016-09-30 | $241.00M | 45.18% |
| 2016-06-30 | $166.00M | -1.19% |
| 2016-03-31 | $168.00M | -22.58% |
| 2015-12-31 | $217.00M | -65.28% |
| 2015-09-30 | $625.00M | -61.47% |
| 2015-06-30 | $1.62B | 156.65% |
| 2015-03-31 | $632.00M | -56.89% |
| 2014-12-31 | $1.47B | 138.37% |
| 2014-09-30 | $615.00M | 18.04% |
| 2014-06-30 | $521.00M | -31.63% |
| 2014-03-31 | $762.00M | 25300.00% |
| 2013-12-31 | $3.00M | -99.33% |
| 2013-09-30 | $446.00M | 48.17% |
| 2013-06-30 | $301.00M | -5.35% |
| 2013-03-31 | $318.00M | 1.92% |
| 2012-12-31 | $312.00M | -61.58% |
| 2012-09-30 | $812.00M | 310.10% |
| 2012-06-30 | $198.00M | 11.86% |
| 2012-03-31 | $177.00M | -25.63% |
| 2011-12-31 | $238.00M | -53.88% |
| 2011-09-30 | $516.00M | 58.28% |
| 2011-06-30 | $326.00M | -35.45% |
| 2011-03-31 | $505.00M | 11.97% |
| 2010-12-31 | $451.00M | -41.81% |
| 2010-09-30 | $775.00M | 224.27% |
| 2010-06-30 | $239.00M | -72.14% |
| 2010-03-31 | $858.00M | 94.56% |
| 2009-12-31 | $441.00M | -30.00% |
| 2009-09-30 | $630.00M | -27.75% |
| 2009-06-30 | $872.00M | 66.10% |
| 2009-03-31 | $525.00M | -33.96% |
| 2008-12-31 | $795.00M | -57.85% |
| 2008-09-30 | $1.89B | 1906.38% |
| 2008-06-30 | $94.00M | -87.86% |
| 2008-03-31 | $774.00M | 6.91% |
| 2007-12-31 | $724.00M | -30.78% |
| 2007-09-30 | $1.05B | 37.63% |
| 2007-06-30 | $760.00M | - |
Dyne Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Dyne Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.89M |
| CYTK | Cytokinetics | $7.53M | $463.00K |
| PLRX | Pliant Therapeutics | $1.58M | - |
| KRTX | Karuna Therapeutics | $654.00K | - |
| DSGN | Design Therapeutics | - | - |
| CGEM | Cullinan Oncology | - | - |
| GRCL | Gracell Bio | - | - |
| DICE | DICE Therapeutics | - | - |
| DYN | Dyne Therapeutics | - | - |
| ERAS | Erasca | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |